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Localisation and pharmacological properties of the VIP receptor in human lung sections are described. The 
receptor density determined by saturation analysis using 1251-VIP is approx. 100 fmol/mg protein, with a 
Kd of approx. 600 pM. Inhibition of lzsI-VIP binding with VIP and related peptides gives a rank order of 
potency: VIP > peptide histidine methionine > secretin. Light microscope autoradiography reveals specific 
VIP binding sites, with a high density over the pulmonary artery smooth muscle and the alveolar walls and 
with a lower density over the bronchial epithelium. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Vasoactive intestinal peptide (VIP) is a potent 
bronchodilator in man [l] and other species [2,3], 
and also relaxes mammalian pulmonary vascular 
smooth muscle [4]. VIP-immunoreactive nerves 
have been demonstrated in association with mam- 
malian airways and pulmonary vessels [5,6], sug- 
gesting a possible physiological role for VIP in 
these locations. A high-affinity VIP receptor 
coupled to adenylate cyclase has been described in 
lung membrane preparations of the rat, mouse and 
guinea pig [7,8]. Recently, a method for preparing 
human lung membranes free of carbon contamina- 
tion has been described, and using this technique a 
high-affinity VIP binding site in the human lung 
has been characterised [9]. The localisation of VIP 
receptors by in vitro autoradiography has been 
reported in the rat lung, showing a high density of 
binding over the alveoli and the epithelium and 
muscular tunica of bronchi [lo]. We now report 
the autoradiographic localisation of specific 1251- 
VIP binding sites in human lung sections, and the 
pharmacological characteristics of these binding 
sites. 
2.1. Tissue preparation 
Human lung specimens were obtained either 
from surgical resection or post-mortem (within 12 
h), insufflated with tissue-embedding medium 
(Tissue-Tek OCT compound) diluted 1:4 with 
phosphate-buffered saline, and rapidly frozen in 
isopentane cooled in liquid nitrogen. Lung sections 
were cut in a cryostat (Slee, London) set at - 2O”C, 
and thaw-mounted onto microscope slides which 
had previously been coated with gelatine and im- 
mersed in 0.3% polyethyleneimine overnight. This 
was to reduce the high degree of non-specific VIP 
binding to the gelatine. After mounting, tissue sec- 
tions were stored at -20°C until required. 
2.2. Biochemical studies 
Saturation data was obtained by incubating 
20 pm sections for 2 h at room temperature with 
100-1500 pM ‘251-VIP in 25 mM Tris-HCl, 5 mM 
MgClz, 0.5% bovine serum albumin and 0.1% 
bacitracin (pH 7.4). Non-specific binding was 
defined by the presence of 1 pM unlabelled VIP. 
After incubation, the slides were washed for 
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2 x 15 min in cold buffer (25 mM Tris-HCl, 5 mM 
MgCl2, pH 7.4) and wiped onto glass fibre filters 
(Whatman, GF-C) to be counted by conventional 
y-counting techniques. Pre~mina~ studies estab- 
lished the optimal incubation and washing times. 
& and Bmax values were calculated by non-linear 
regression analysis. Representative sections were 
sonicated and protein content was determined ac- 
cording to Lowry et al. [ll], with bovine serum 
albumin as the protein standard. 
The inhibition of “‘I-VIP binding by VIP, pep- 
tide histidine methionine (PHM) and secretin was 
studied by incubating sections with 250 pM “‘I- 
VIP and varying amounts of the competing pep- 
tide. Ki values were calculated by the Cheng and 
Prusoff equation [121. 
2.3. Autoradiography 
12bm sections were incubated with 400 pM **?- 
VIP and washed as described above. Non-specific 
binding was defined by the presence of 3 PM 
PHM. After washing, the slides were rapidly dried 
in a stream of cold air and stored with desiccant 
under vacuum overnight. Autoradiography was 
performed by a modification of the method de- 
scribed by Young and Kuhar [ 131. Emulsion @ford 
K.2) coated coverslips were attached to the slides 
and left in light-tight boxes for an exposure period 
of 3 days. The coverslips were then partially 
separated from the sections so that the emulsion 
could be developed (Ilford Phenisol) and the sec- 
tions fixed with Carnoy’s solution and lightly 
stained with 1% pyronine Y. The coverslips were 
mounted onto the slides in their former positions 
and viewed with both light- and dark-field micros- 
COPY. 
2.4. Drugs and chemicals 
*251-VIP was obtained from Amersham (Eng- 
land); unlabelled VIP, secretin, bovine serum 
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Fig. 1. Typical saturation binding curve of specific r2%VIP binding to human lung sections (n = 3, lungs from different 
individuals). Specific binding is not corrected for protein content of the sections. B max range 93-l 11 fmol/mg protein; 
Kd range 480-730 pM. (Inset) Scatchard plot: Abscissa, specific ‘251-VIP binding (fmol); ordinate, the ratio of specific 
‘251-VIP binding (fmol) to the free Iigand concentration (nM). 
199 
Volume 199, number 2 FEBS LETTERS April 1986 
albumin, bacitracin, polyethyleneimine from Sigma 
(Poole, England); PHM from Peninsula Laborato- 
ries (St. Helens, England); Tissue-Tek OCT com- 
pound from Raymond A. Lamb, London. 
3. RESULTS 
3.1. Biochemical studies 
At room temperature the time course i2%VIP 
binding to human lung sections was slow, reaching 
equilibrium at 2 h (not shown). Specific binding 
was saturable and of high affinity with a & of 
480-730 pM (n=3) and a receptor density of 
93-111 fmol/mg protein (n=3) (fig.1). Over the 
concentration range studied, Scatchard analysis 
1141 described a single ~pulation of binding sites; 
however, at higher concentrations the Scatchard 
plot became curvilinear indicating the presence of 
a second population of binding sites of low affinity 
(not shown). At low concentrations of ‘2”I-VIP the 
non-specific binding as defined by 1 ,ulM unlabelled 
VIP was 1%20% of the total binding. 
Displacement XI ‘ves for VIP and related pep- 
tides are shown in fig.2. The order of potency of 
these peptides was VIP (Ki 0.88-l .86 nM, n = 3)> 
PHM (Ki 19.3-75.7 nM, n=3)>secretin (0,62- 
5.54 pM, n = 3). The Hill slope factors in all cases 
were less than 1 (nH VIP and PHM = 0.75, nH 
secretin = 0.55), indicating that these peptides are 
agonists at the VIP receptor. 
3.2. Autoradiography 
Autoradiography revealed specific 12JI-VIP 
binding sites throughout human lung. After in- 
cubation with iz51-VIP alone, binding was concen- 
trated over tissue with no elevation of grain density 
above background in the interstitial spaces. It was 
thought preferable to use a ligand other than VIP 
to demonstrate non-specific binding and displace- 
ment studies showed that 3 pM PHM inhibited 
VIP binding to the same extent as 1 FM VIP 
(fig.2). Adjacent sections incubated with ‘251-VIP 
in the presence of 3 pM PHM showed relatively 
few autoradiographic grains and in general grain 
density did not conform to the pattern of the 
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Fig 2 Inhibition of “‘I-VIP binding by unlabelled VIP, PHM and secretin. Typical curves from n = 3. Ki ranges: VIP, . . 
0.88-1.86 nM; PHM, 19.3-75.7 nM; secretin, (X62-5.54 FM. 
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Fig.3. Distribution of 12sI-VIP binding in human lung. (a) Light-field photomicrograph of a section of human lung 
showing pulmonary artery wall (internal diameter 2 mm) and alveoli. (b) Dark-field autoradiograph of the same area 
incubated with 400 pM ‘2sI-VIP showing dense labelling of arterial smooth muscle and alveoli. (c) Adjacent section in- 
cubated with ‘2’I-VIP in the presence of 3 PM PHM, showing no specific labelling. (d) Photomicrograph of a section 
of bronchial wall (internal diameter 5 mm). (e) Dark-field autoradiograph of the same area showing ‘*‘I-VIP binding 
over the epithelium. (f) Adjacent section incubated with ‘z51-VIP and 3 pM PHM. SM, smooth muscle; Ad, adventitia; 
A, alveoli; Epi, epithelium. 
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underlying tissue. Exceptions to this were non- tissue 161. It is possible that these binding sites may 
displaceable “‘I-VIP binding over bronchial car- represent a receptor for circulating VIP [lo] or 
tilage, mucous glands and carbon particles. may be important in its metabolism [19]. 
Specific grain density was highest over alveoli 
and pulmonary artery smooth muscle, irrespective 
of artery size, with fewer grains present over the 
bronchi (fig.3). Within the bronchi, grains were 
localised to the epithelium with no specific binding 
to bronchial smooth muscle. This was observed in 
airways of all sizes, inchtding extrapulmonary 
bronchus. 
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